Westchester Medical Center Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2017
NCT03056378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Westchester Medical Center | Westchestr Medical Center

Active Ingredients

Drugs in Phase 3 Trials (2)

ampicillin (1 trial)

gentamicin (garamycin) (1 trial)

Drugs in Phase 2 Trials (6)

acetylsalicylic acid (aspirin) (1 trial)

calcium (1 trial)

neuropeptide Y (1 trial)

selenium (1 trial)

thyroxine (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (1)

red blood cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Hemorrhage (Phase 2)

Disease (Phase 2)

Hemorrhage (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Stress Disorders, Traumatic, Acute (Phase 2)

Transfusion Reaction (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 9